Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVSRIPO in Recurrent Pediatric Malignant Glioma
NCT03043391Phase 1Completed
- Sponsor
- Istari Oncology
- Start
- Nov 2017
- Primary completion
- Mar 2022
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lerapolturev in malignant glioma, sponsored by Istari Oncology. Primary endpoints: Percentage of Participants With Unacceptable Toxicity at 14 days and Percentage of Participants Requiring Low-dose Bevacizumab or Steroid at 1 year. Started Nov 2017; status: completed.
02
Drugs
lerapolturev
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT03043391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043391.